[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY32947A - Compuestos de pirrolo[2,3-d]pirimidina - Google Patents

Compuestos de pirrolo[2,3-d]pirimidina

Info

Publication number
UY32947A
UY32947A UY0001032947A UY32947A UY32947A UY 32947 A UY32947 A UY 32947A UY 0001032947 A UY0001032947 A UY 0001032947A UY 32947 A UY32947 A UY 32947A UY 32947 A UY32947 A UY 32947A
Authority
UY
Uruguay
Prior art keywords
compounds
pyrimidine
pirrolo
jak
pyrrolo
Prior art date
Application number
UY0001032947A
Other languages
English (en)
Inventor
Brad Alan Acker
Susan J Hartmann
Horng-Chih Huang
Eric Jon Jacobsen
Michele Ann Promo
Sergey Gregory Wolfson
Xie Jin
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY32947A publication Critical patent/UY32947A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento están descritos compuestos de pirrolo[2,3-d]pirimidina, su uso como inhibidores de quinasa de Janus (JAK), composiciones farmacéuticas que contienen estos compuestos y procedimientos para su preparación.
UY0001032947A 2009-10-15 2010-10-15 Compuestos de pirrolo[2,3-d]pirimidina UY32947A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25203909P 2009-10-15 2009-10-15

Publications (1)

Publication Number Publication Date
UY32947A true UY32947A (es) 2011-05-31

Family

ID=43413616

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032947A UY32947A (es) 2009-10-15 2010-10-15 Compuestos de pirrolo[2,3-d]pirimidina

Country Status (28)

Country Link
US (1) US8633206B2 (es)
EP (1) EP2488524B1 (es)
JP (1) JP5629324B2 (es)
KR (1) KR20120083452A (es)
CN (1) CN102574860A (es)
AP (1) AP2012006192A0 (es)
AR (1) AR078635A1 (es)
AU (1) AU2010308028A1 (es)
CA (1) CA2776028C (es)
CL (1) CL2012000795A1 (es)
CO (1) CO6531451A2 (es)
CR (1) CR20120164A (es)
CU (1) CU20120059A7 (es)
DO (1) DOP2012000080A (es)
EA (1) EA201290147A1 (es)
EC (1) ECSP12011855A (es)
ES (1) ES2426407T3 (es)
IL (1) IL218802A0 (es)
IN (1) IN2012DN02577A (es)
MA (1) MA33670B1 (es)
MX (1) MX2012004379A (es)
NI (1) NI201200053A (es)
PE (1) PE20121077A1 (es)
TN (1) TN2012000146A1 (es)
TW (1) TWI398444B (es)
UY (1) UY32947A (es)
WO (1) WO2011045702A1 (es)
ZA (1) ZA201202718B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370451B1 (en) 2008-12-02 2016-11-16 Wave Life Sciences Japan, Inc. Method for the synthesis of phosphorus atom modified nucleic acids
BRPI1013559A2 (pt) 2009-03-23 2016-04-12 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos
BRPI1013705A2 (pt) 2009-03-23 2016-04-05 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
CA2782720A1 (en) * 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
AU2012284265B2 (en) 2011-07-19 2017-08-17 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
JP6123804B2 (ja) 2011-08-12 2017-05-10 日産化学工業株式会社 ３環性ヘテロ環化合物及びｊａｋ阻害剤
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
US8957104B2 (en) * 2012-07-17 2015-02-17 Glaxosmithkline Intellectual Property (No. 2) Limited Chemical compounds
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
JP6248948B2 (ja) 2013-02-08 2017-12-20 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
PL2958921T3 (pl) 2013-02-22 2018-01-31 Pfizer Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinaz janusowych (jak)
SG11201509029PA (en) 2013-05-02 2015-12-30 Hoffmann La Roche Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
SG10201912897UA (en) 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2015174376A1 (ja) 2014-05-14 2015-11-19 日産化学工業株式会社 ３環性化合物及びｊａｋ阻害剤
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
KR102124449B1 (ko) * 2016-02-16 2020-06-26 조에티스 서비시즈 엘엘씨 7H-피롤로[2,3-d]피리미딘 화합물을 제조하기 위한 방법
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
BR112021014525A8 (pt) * 2019-01-30 2022-11-22 Gargamel Zhuhai Biotech Ltd Inibidor de jak e método de preparação do mesmo
IL264854A (en) * 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
EP3993793A4 (en) * 2019-07-01 2023-06-28 Ligang Qian P2x7r antagonists
EP4021452B1 (en) * 2019-08-26 2023-12-20 Chemwerth Inc Substituted (7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino compounds useful as jak1 inhibitors
CN115246833B (zh) * 2021-04-27 2024-08-13 洛阳惠中兽药有限公司 一种奥拉替尼化合物及其中间体化合物的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
ES2208433T3 (es) 1999-12-10 2004-06-16 Pfizer Products Inc. Compuestos de pirrolo(2,3-d)pirimidina como inhibidores de proteina quinasas.
AP1911A (en) 2000-06-26 2008-10-30 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds.
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
CN1726192A (zh) 2002-11-21 2006-01-25 辉瑞产品公司 3－氨基－哌啶衍生物及其制备方法
AU2004268621C1 (en) * 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
WO2005047289A1 (en) 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
CN1926140A (zh) 2004-03-05 2007-03-07 大正制药株式会社 吡咯并嘧啶衍生物
EP1773826A4 (en) * 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
KR101312225B1 (ko) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
WO2007012953A2 (en) 2005-07-29 2007-02-01 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
US8580802B2 (en) 2005-09-30 2013-11-12 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1990335A4 (en) * 2006-03-02 2009-11-11 Astellas Pharma Inc 17-BETA-HSD-type-5 INHIBITOR
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009115084A2 (de) 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
MX2011001904A (es) * 2008-08-20 2011-03-29 Pfizer Compuestos de pirrolo[2,3-d]pirimidina.

Also Published As

Publication number Publication date
ECSP12011855A (es) 2012-06-29
TN2012000146A1 (fr) 2013-09-19
TWI398444B (zh) 2013-06-11
AR078635A1 (es) 2011-11-23
JP2013508266A (ja) 2013-03-07
CU20120059A7 (es) 2012-06-29
US20110136765A1 (en) 2011-06-09
DOP2012000080A (es) 2012-06-15
EP2488524B1 (en) 2013-07-03
CA2776028A1 (en) 2011-04-21
CO6531451A2 (es) 2012-09-28
CR20120164A (es) 2012-11-07
NI201200053A (es) 2012-08-09
IN2012DN02577A (es) 2015-08-28
CL2012000795A1 (es) 2012-09-07
CN102574860A (zh) 2012-07-11
MX2012004379A (es) 2012-06-01
AU2010308028A1 (en) 2012-04-19
EA201290147A1 (ru) 2012-11-30
US8633206B2 (en) 2014-01-21
CA2776028C (en) 2015-12-01
JP5629324B2 (ja) 2014-11-19
PE20121077A1 (es) 2012-08-10
KR20120083452A (ko) 2012-07-25
TW201125866A (en) 2011-08-01
MA33670B1 (fr) 2012-10-01
AP2012006192A0 (en) 2012-04-30
ES2426407T3 (es) 2013-10-23
IL218802A0 (en) 2012-06-28
ZA201202718B (en) 2012-12-27
WO2011045702A1 (en) 2011-04-21
EP2488524A1 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
ECSP12011855A (es) COMPUESTOS DE pIrrolo[2,3-d]pIrimidinA
ECSP11010904A (es) Compuestos de pirrolo[2,3-d]pirimidina
CR20150395A (es) Derivados de pirrolo[2,3-d] pirimidina
BR112012019511A2 (pt) compostos de pirrolo [2,3-d] pirimidina como inibidores de jak.
ECSP11011181A (es) Compuestos orgánicos
ECSP11011185A (es) Compuestos orgánicos
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
DOP2011000175A (es) Compuestos organicos
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
UY33130A (es) Derivados de imidazopiridina como inhibidores de jak
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
MX2015010858A (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
ECSP10010389A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
CU20130124A7 (es) Derivados de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritmia
CY1115106T1 (el) Ενωσεις πυρρολο[2,3-d]πυριμιδινης
NI201200162A (es) Inhibidores de pirazolil quinoxalina cinasa

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190221